The treatment of anti-phospholipid syndrome: A comprehensive clinical approach

Journal of Autoimmunity

Volumn 90, Issue , 2018, Pages 1-27

  Chighizola, Cecilia Beatrice ^a,b,c   Andreoli, Laura ^d   Gerosa, Maria ^a,b,e   Tincani, Angela ^d   Ruffatti, Amelia ^f   Meroni, Pier Luigi ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c Clinical Immunology and Rheumatology   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti phospholipid antibodies; Anti phospholipid syndrome; Asymptomatic carriers; Catastrophic anti phospholipid syndrome; Obstetric complications; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ECULIZUMAB; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; RAPAMYCIN; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTITHROMBOCYTIC AGENT; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; APHERESIS; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; MEDICAL DECISION MAKING; NONHUMAN; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; TERMINAL DISEASE; THROMBOSIS PREVENTION; VEIN THROMBOSIS; ANIMAL; AUTOIMMUNITY; COMBINATION DRUG THERAPY; FEMALE; IMMUNOLOGY; METABOLISM; PREGNANCY; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 85041948348     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2018.02.003     Document Type: Review

References (317)

1. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemostasis 4 (2006), 295–306.
2. Biggioggero, M., Meroni, P.L., The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun. Rev. 9 (2010), A299–A304.
3. Meroni, P.L., Raschi, E., Grossi, C., Pregnolato, F., Trespidi, L., Acaia, B., Borghi, M.O., Obstetric and vascular APS: same autoantibodies but different diseases?. Lupus 21 (2012), 708–710.
4. Alijotas-Reig, J., Ferrer-Oliveras, R., Ruffatti, A., Tincani, A., Lefkou, E., Bertero, M.T., et al. (EUROAPS study group collaborators), the European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun. Rev. 14 (2015), 387–395.
5. Pelkmans, L., de Laat, B., Antibodies against domain I of β2-glycoprotein I: the one and only?. Lupus 21 (2012), 769–772.
6. Chighizola, C.B., Gerosa, M., Meroni, P.L., New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr. Rheumatol. Rep. 16 (2014), 402–407.
7. Chighizola, C.B., Raschi, E., Banzato, A., Borghi, M.O., Pengo, V., Meroni, P.L., The challenges of lupus anticoagulants. Expet Rev. Hematol. 9 (2016), 389–400.
8. Meroni, P.L., Chighizola, C.B., Rovelli, F., Gerosa, M., Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res. Ther., 16, 2014, 209.
9. Chighizola, C.B., Borghi, M.O., Meroni, P.L., Antibodies and diagnostic tests in antiphospholipid syndrome. Tzokos, G.C., (eds.) Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects, 2016, Elsevier Inc., 495–501.
10. Chighizola, C.B., Raschi, E., Borghi, M.O., Meroni, P.L., Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr. Opin. Rheumatol. 27 (2015), 476–482.
11. Baroni, G., Banzato, A., Bison, E., Denas, G., Zoppellaro, G., Pengo, V., The role of platelets in antiphospholipid syndrome. Platelets 28 (2017), 762–766.
12. Knight, J.S., Meng, H., Coit, P., Yalavarthi, S., Sule, G., Gandhi, A.A., et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. J.C.I. Insight, 21, 2017.
13. Pierangeli, S.S., Girardi, G., Vega-Ostertag, M., Liu, X., Espinola, R.G., Salmon, J., Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 52 (2005), 2120–2124.
14. Fischetti, F., Durigutto, P., Pellis, V., Debeus, A., Macor, P., Bulla, R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106 (2005), 2340–2346.
15. Agostinis, C., Durigutto, P., Sblattero, D., Borghi, M.O., Grossi, C., et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123 (2014), 3478–3487.
16. Romay-Penabad, Z., Carrera Marin, A., Willis, R., Weston-Davies, W., Machin, S., Cohen, H., et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 23 (2014), 1324–1326.
17. Agostinis, C., Biffi, S., Garrovo, C., Durigutto, P., Lorenzon, A., Bek, A., et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 118 (2011), 4231–4238.
18. Poulton, K., Ripoll, V.M., Pericleous, C., Meroni, P.L., Gerosa, M., Ioannou, Y., et al. Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. Am. J. Reprod. Immunol. 73 (2015), 390–401.
19. Viall, C.A., Chamley, L.W., Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun. Rev. 14 (2015), 446–471.
20. Abrahams, V.M., Chamley, L.W., Salmon, J.E., Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation. Arthritis Rheum. 69 (2017), 1710–1721.
21. Rand, J.H., Wu, X.X., Guller, S., Gil, J., Guha, A., Scher, J., Lockwood, C.J., Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol. 171 (1994), 1566–1572.
22. Salafia, C.M., Cowchock, F.S., Placental pathology and antiphospholipid antibodies: a descriptive study. Am. J. Perinatol. 14 (1997), 435–441.
23. Sebire, N.J., Fox, H., Backos, M., Rai, R., Paterson, C., Regan, L., Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum. Reprod. 17 (2002), 1067–1071.
24. Kitchens, C.S., Thrombotic storm: when thrombosis begets thrombosis. Am. J. Med. 104 (1998), 381–385.
25. Amital, H., Levy, Y., Davidson, C., Lundberg, I., Harju, A., Kosach, Y., Asherson, R.A., Shoenfeld, Y., Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Semin. Arthritis Rheum. 31 (2001), 127–132.
26. Bontadi, A., Ruffatti, A., Falcinelli, E., Giannini, S., Marturano, A., Tonello, M., et al. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb. Haemostasis 109 (2013), 901–908.
27. Agmon-Levin, N., Rosário, C., Katz, B.-S.P., Zandman-Goddard, G., Meroni, P., Cervera, R., et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus 22 (2013), 1327–1335.
28. Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E.G., D'Cruz, D.P., Shoenfeld, Y., The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med., 11, 2013, 185.
29. Oku, K., Amengual, O., Atsumi, T., Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur. J. Clin. Invest. 42 (2012), 1126–1135.
30. Ritis, K., Doumas, M., Mastellos, D., Micheli, A., Giaglis, S., Magotti, P., et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177 (2006), 4794–4802.
31. Asherson, R., Shoenfeld, Y., The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome–molecular mimicry?. J. Rheumatol. 27 (2000), 12–14.
32. Rodríguez-Pintó I., Moitinho, M., Santacreu, I., Shoenfeld, Y., Erkan, D., Espinosa, G., Cervera, R., Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun. Rev. 15 (2016), 1120–1124.
33. Andreoli, L., Chighizola, C.B., Banzato, A., Pons-Estel, G.J., Ramires de Jesus, G., Erkan, D., Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 65 (2013), 1869–1873.
34. Cervera, R., Khamashta, M.A., Shoenfeld, Y., Camps, M.T., Jacobsen, S., Kiss, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 68 (2009), 1428–1432.
35. Cervera, R., Piette, J.C., Font, J., Khamashta, M.A., Shoenfeld, Y., Camps, M.A.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46 (2002), 1019–1027.
36. Pengo, V., Ruffatti, A., Legnani, C., Gresele, P., Barcellona, D., Erba, N., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemostasis 8 (2010), 237–242.
37. Gerosa, M., Meroni, P.L., Erkan, D., Recognition and management of antiphospholipid syndrome. Curr. Opin. Rheumatol. 28 (2016), 51–59.
38. Erkan, D., Derksen, R., Levy, R., Machin, S., Ortel, T., Pierangeli, S., et al. Antiphospholipid syndrome clinical research task force report. Lupus 20 (2011), 219–224.
39. Radin, M., Cecchi, I., Roccatello, D., Meroni, P.L., Sciascia, S., Prevalence and thrombotic risk assessment of anti-β2 glycoprotein I domain I antibodies: a systematic Review. Semin. Thromb. Hemost., 2017, 10.1055/s-0037–1603936.
40. Ruffatti, A., Del Ross, T., Ciprian, M., Nuzzo, M., Rampudda, M., Bertero, M.T., Bergia, R., Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann. Rheum. Dis. 68 (2009), 397–399.
41. Finazzi, G., Marchioli, R., Brancaccio, V., Schinco, P., Wisloff, F., Musial, J., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemostasis 3 (2005), 848–853.
42. Ruiz-Irastorza, G., Hunt, B.J., Khamashta, M.A., A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 57 (2007), 1487–1495.
43. Bala, M.M., Celinska-Lowenhoff, M., Szot, W., Padjas, A., Kaczmarczyk, M., Swierz, M.J., Undas, A., Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome, Cochrane. Database. Syst. Rev., 10, 2017, 10.1002/14651858.CD012169.pub2.
44. Crowther, M.A., Ginsberg, J.S., Julian, J., Denburg, J., Hirsch, J., Douketis, J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349 (2003), 1133–1138.
45. Rosborough, T.K., Shepherd, M.F., Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 24 (2004), 838–842.
46. th International Congress on antiphospholipid antibodies. Lupus 20 (2011), 206–218.
47. Yelnik, C.M., Urbanski, G., Drumez, E., Caron, C., Maillard, H., Morell-Dubois, S., et al. Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. Lupus, 93, 2017, 10.1177/0961203317721751.
48. Schulman, S., Svenungsson, E., Granqvist, S., Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104 (1998), 332–338.
49. Bazzan, M., Vaccarino, A., Stella, S., Bertero, M.T., Carignola, R., Montaruli, B., et al. Anti-phospholipid Piedemont Consortium, Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun. Rev. 12 (2013), 26–31.
50. Garcia, D., Akl, E.A., Carr, R., Kearon, C., Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122 (2013), 817–824.
51. Coloma Bazán, E., Donate López, C., Moreno Lozano, P., Cervera, R., Espinosa, G., Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol. Res. 56 (2013), 358–361.
52. Sciascia, S., Coloma-Bazán, E., Radin, M., Bertolaccini, M.L., López-Pedrera, C., Espinosa, G., et al. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?. Autoimmun. Rev. 16 (2017), 1109–1114.
53. Jackson, W.G., Oromendia, C., Unlu, O., Erkan, D., DeSancho, M.T., Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood. Adv. 1 (2017), 2320–2324.
54. Tan, B.E., Thong, B.Y.H., Shivananda, S., Han, W.W., Chng, H.H., Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus 18 (2009), 752–775.
55. Levine, S.R., Brey, R.L., Tilley, B.C., Thompson, J.L., Sacco, R.L., Sciacca, R.R., et al., the APASS Investigators, Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, J. Am. Med. Assoc. 291 (2004), 576–584.
56. Radin, M., Schreiber, K., Cecchi, I., Roccatello, D., Cuadrado, M.J., Sciascia, S., The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study. Eur. J. Neurol. 4 (2017), 295–299.
57. Erkan, D., Harrison, M.J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56 (2007), 2382–2391.
58. Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramon, E., et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 74 (2015), 1011–1018.
59. Andrade, D., Cervera, R., Cohen, H., Crowther, M., Cuadrado, M.J., Canaud, G., et al. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. Antiphospholipid Syndrome, vol. 4, 2017, Springer International Publishing, Cham, 317–338.
60. Rand, J.H., Wu, X.-X., Quinn, A.S., Chen, P.P., Hathcock, J.J., Taatjes, D.J., Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112 (2008), 1687–1695.
61. Rand, J.H., Wu, X.-X., Quinn, A.S., Ashton, A.W., Chen, P.P., Hathcock, J.J., Andree, H.A., Taatjes, D.J., Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115 (2010), 2292–2299.
62. Müller-Calleja, N., Hollerbach, A., Häuser, F., Canisius, A., Orning, C., Lackner, K.J., Antiphospholipid antibody-induced cellular responses depend on epitope specificity: implications for treatment of antiphospholipid syndrome. J. Thromb. Haemostasis 15 (2017), 2367–2376.
63. Espinola, R.G., Pierangeli, S.S., Gharavi, A.E., Harris, E.N., Ghara, A.E., Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemostasis 87 (2002), 518–522.
64. Edwards, M.H., Pierangeli, S., Liu, X., Barker, J.H., Anderson, G., Harris, E.N., Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (1997), 4380–4384.
65. Petri, M., Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13 (2011), 77–80.
66. Tektonidou, M.G., Laskari, K., Panagiotakos, D.B., Moutsopoulos, H.M., Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61 (2009), 29–36.
67. Schmidt-Tanguy, A., Voswinkel, J., Henrion, D., Subra, J.F., Loufrani, L., Rohmer, V., et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J. Thromb. Haemostasis 11 (2013), 1927–1929.
68. Nuri, E., Taraborelli, M., Andreoli, L., Tonello, M., Gerosa, M., Calligaro, A., et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res. 65 (2017), 17–24.
69. Khattri, S., Zandman-Goddard, G., Peeva, E., B-cell directed therapies in antiphospholipid antibody syndrome-new directions based on murine and human data. Autoimmun. Rev. 11 (2012), 717–722.
70. Erkan, D., Vega, J., Ramón, G., Kozora, E., Lockshin, M.D., A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 65 (2013), 464–471.
71. Erkan, D., Aguiar, C.L., Andrade, D., Cohen, H., Cuadrado, M.J., Danowski, A., et al. 14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun. Rev. 13 (2014), 685–696.
72. Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Perez-Alvarez, R., Brito-Zerón, P., Ramos-Casals, M., Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expet Opin. Drug Saf. 16 (2017), 1255–1271.
73. Meroni, P.L., Macor, P., Durigutto, P., De Maso, L., Gerosa, M., Ferraresso, M., et al. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood 127 (2016), 365–367.
74. Chighizola, C.B., Ubiali, T., Meroni, P.L., Treatment of thrombotic antiphospholipid syndrome: the Rationale of current management- an insight into future approaches. J. Immunol. Res., 2015 951424–20volume: 2015; year: 2015; article ID: 951424, page range: 1-20.
75. Tenti, S., Cheleschi, S., Guidelli, G.M., Galeazzi, M., Fioravanti, A., Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature. Autoimmun. Rev. 15 (2016), 226–235.
76. Sciascia, S., Giachino, O., Roccatello, D., Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin. Exp. Rheumatol. 30 (2012), 409–413.
77. Burnett, A.E., Mahan, C.E., Vazquez, S.R., Oertel, L.B., Garcia, D.A., Ansell, J., Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J. Thromb. Thrombolysis 41 (2016), 206–232.
78. Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R.J., Mackie, I.J., Clawson, S., et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet. Haematol. 3 (2016), e426–e436.
79. Woller, S.C., Stevens, S.M., Kaplan, D.A., T Rondina, M., Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. Clin. Appl. Thromb. Hemost., 24, 2018, 192.
80. Bachmeyer, C., Elalamy, I., Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome. Clin. Exp. Dermatol. 39 (2014), 840–841.
81. Win, K., Rodgers, G.M., New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am. J. Hematol., 89, 2014, 1017.
82. Schaefer, J.K., McBane, R.D., Black, D.F., Williams, L.N., Moder, K.G., Wysokinski, W.E., Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb. Haemostasis 112 (2014), 947–950.
83. Noel, N., Dutasta, F., Costedoat-Chalumeau, N., Bienvenu, B., Mariette, X., Geffray, L., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun. Rev. 14 (2015), 680–685.
84. Delgado, M.G., Corte, J.R., Sáiz, A., Calleja, S., Recurrent lacunar ischaemic stroke due to resistance to antiplatelet treatment: examining the need for personalised antithrombotic therapy. Neurologia 30 (2015), 376–378.
85. Sugie, M., Iizuka, N., Shimizu, Y., Ichikawa, H., Cerebral venous thromboembolism in antiphospholipid syndrome successfully treated with the combined use of an anti-Xa inhibitor and corticosteroid. Intern. Med. 54 (2015), 3051–3056.
86. Sciascia, S., Breen, K., Hunt, B.J., Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul. Fibrinolysis 26 (2015), 476–477.
87. Son, M., Wypasek, E., Celinska-Lowenhoff, M., Undas, A., The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb. Res., 1, 2015, 2.
88. Signorelli, F., Nogueira, F., Domingues, V., Mariz, H.A., Levy, R.A., Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin. Rheumatol. 35 (2016), 801–805.
89. Betancur, J.F., Bonilla-Abadía, F., Hormaza, A.A., Jaramillo, F.J., Cañas, C.A., Tobón, G.J., Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus 25 (2016), 658–662.
90. Rokos, J., Heger, M., Stöllberger, C., Finsterer, J., Laufer, G., Wiedemann, D., Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban. Int. J. Cardiol. 221 (2016), 383–384.
91. Haładyj, E., Olesińska, M., Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia 54 (2016), 146–149.
92. Resseguier, A.S., Pereira, B., Rieu, V., Le Guenno, G., Grobost, V., Ruivard, M., Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?. Lupus 26 (2017), 1297–1303.
93. Mateos Rodríguez, J.J., Bellido, D., Castro, D., Portillo Sánchez, J., Vanegas, R., Núñez García, A., After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: a report of 2 cases. Reumatol. Clín., 2017, 10.1016/j.reuma.2017.04.010.
94. Joshi, A., Hong, J., Siva, C., Recurrent thrombosis in patients with antiphospholipid syndrome receiving newer oral anticoagulants: a case report and review of literature. Clin. Med. Res. 15 (2017), 41–44.
95. Malec, K., Góralczyk, T., Undas, A., The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb. Res. 152 (2017), 93–97.
96. Crowley, M.P., Cuadrado, M.J., Hunt, B.J., Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. Thromb. Res. 153 (2017), 37–39.
97. Canaud, G., Bienaimé F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.H., et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371 (2014), 303–312.
98. Mora-Ramírez, M., González-Pacheco, H., Amezcua-Guerra, L.M., Stents coated with mammalian target of rapamycin inhibitors (mTOR) appear to be the best choice in patients with antiphospholipid syndrome and myocardial infarction. J. Clin. Rheumatol., 22, 2016, 281.
99. Chighizola, C.B., Raimondo, M.G., Meroni, P.L., Management of thrombotic antiphospholipid syndrome. Semin. Thromb. Hemost., 2017, 10.1055/s-0036-1597282.
100. Silver, R.M., Parker, C.B., Reddy, U.M., Goldenberg, R., Coustan, D., Dudley, D.J., et al. Antiphospholipid antibodies in stillbirth. Obstet. Gynecol. 122 (2013), 641–657.
101. Ruffatti, A., Tonello, M., Visentin, M.S., Bontadi, A., Hoxha, A., de Carolis, S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology 50 (2011), 1684–1689.
102. Ruffatti, A., Tonello, M., del Ross, T., Cavazzana, A., Grava, C., Noventa, F., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb. Haemostasis 96 (2006), 337–341.
103. Latino, J.O., Udry, S., Aranda, F.M., Perés Wingeyer, S.D.A., Fernández Romero, D.S., de Larrañaga, G.F., Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus 26 (2017), 983–988.
104. Rezk, M., Dawood, R., Badr, H., Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study. J. Matern. Fetal Neonatal Med. 29 (2016), 4015–4019.
105. Lockshin, M.D., Kim, M., Laskin, C.A., Guerra, M., Branch, D.W., Merrill, J., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 64 (2012), 2311–2318.
106. Buyon, J.P., Kim, M.Y., Guerra, M.M., Laskin, C.A., Petri, M., Lockshin, M.D., et al. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann. Intern. Med. 163 (2015), 153–163.
107. Abou-Nassar, K., Carrier, M., Ramsay, T., Rodger, M.A., The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb. Res. 128 (2011), 77–85.
108. Matsuki, Y., Atsumi, T., Yamaguchi, K., Hisano, M., Arata, N., Oku, K., et al. Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications. Mod. Rheumatol. 25 (2015), 215–218.
109. Chighizola, C.B., Andreoli, L., de Jesus, G.R., Banzato, A., Pons-Estel, G.J., Erkan, D., et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus 24 (2015), 980–984.
110. Saccone, G., Berghella, V., Maruotti, G.M., Ghi, T., Rizzo, G., Simonazzi, G., et al. PREGNANTS (PREGNancy in women with ANTiphospholipid Syndrome) working group. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am. J. Obstet. Gynecol., 216, 2017 e1–525.e12.
111. Galli, M., Luciani, D., Bertolini, G., Barbui, T., Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003), 1827–1832.
112. Kitaori, T., Sugiura-Ogasawara, M., Oku, K., Papisch, W., Ebara, T., Ozaki, Y., et al. Determination of clinically significant tests for antiphospholipid antibodies and cutoff levels for obstetric antiphospholipid syndrome. Lupus 24 (2015), 1505–1519.
113. Žigon, P., Perdan Pirkmajer, K., Tomšič M., Kveder, T., Božič B., Sodin Šemrl, S., et al. Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes. J. Immunol. Res., 2015, 2015, 975704.
114. Hoxha, A., Mattia, E., Tonello, M., Grava, C., Pengo, V., Ruffatti, A., Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin. Chem. Lab. Med. 55 (2017), 890–898.
115. de Carolis, S., Botta, A., Santucci, S., Garofalo, S., Martino, C., Perrelli, A., et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin. Rev. Allergy Immunol. 38 (2010), 116–124.
116. Reggia, R., Ziglioli, T., Andreoli, L., Bellisai, F., Iuliano, A., Gerosa, M., et al. Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. Rheumatology 51 (2012), 2186–2190.
117. Bramham, K., Hunt, B.J., Germain, S., Calatayud, I., Khamashta, M., Bewley, S., et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19 (2010), 58–64.
118. Fischer-Betz, R., Specker, C., Brinks, S., Schneider, M., Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 21 (2012), 1183–1189.
119. Elder, M.G., de Swiet, M., Robertson, A., Elder, M.A., Flloyd, E., Hawkins, D.F., Low-dose aspirin in pregnancy. Lancet, 1, 1988, 410.
120. Carmona, F., Font, J., Azulay, M., Creus, M., Fábregues, F., Cervera, R., et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am. J. Reprod. Immunol. 46 (2001), 274–279.
121. Silver, R.K., MacGregor, S.N., Sholl, J.S., Hobart, J.M., Neerhof, M.G., Ragin, A., Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am. J. Obstet. Gynecol. 169 (1993), 1411–1417.
122. Lima, F., Khamashta, M.A., Buchanan, N.M., Kerslake, S., Hunt, B.J., Hughes, G.R., A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin. Exp. Rheumatol. 14 (1996), 131–136.
123. Granger, K.A., Farquharson, R.G., Obstetric outcome in antiphospholipid syndrome. Lupus, 1997, 509–513.
124. Huong, D.L., Wechsler, B., Blétry, O., Vauthier-Brouzes, D., Lefebvre, G., Piette, J.C., A study of 75 pregnancies in patients with antiphospholipid syndrome. J. Rheumatol. 28 (2001), 2025–2030.
125. Muñoz-Rodriguez, F.J., Font, J., Cervera, R., Reverter, J.C., Tàssies, D., Espinosa, G., et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin. Arthritis Rheum. 29 (1999), 182–901.
126. Tulppala, M., Marttunen, M., Söderstrom-Anttila, V., Foudila, T., Ailus, K., Palosuo, T., et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum. Reprod. 12 (1997), 1567–1572.
127. Pattison, N.S., Chamley, L.W., Birdsall, M., Zanderigo, A.M., Liddell, H.S., McDougall, J., Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am. J. Obstet. Gynecol. 183 (2000), 1008–1012.
128. Rosove, M.H., Tabsh, K., Wasserstrum, N., Howard, P., Hahn, B.H., Kalunian, K.C., Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet. Gynecol. 75 (1990), 630–634.
129. Fishman, P., Falach-Vaknin, E., Sredni, B., Meroni, P.L., Tincani, A., Dicker, D., et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am. J. Reprod. Immunol. 35 (1996), 80–84.
130. Bose, P., Black, S., Kadyrov, M., Weissenborn, U., Neulen, J., Regan, L., et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am. J. Obstet. Gynecol. 192 (2005), 23–30.
131. Alvarez, A.M., Mulla, M.J., Chamley, L.W., Cadavid, A.P., Abrahams, V.M., Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions. Arthritis Rheum. 67 (2015), 488–497.
132. Di Simone, N., Meroni, P.L., D'Asta, M., Di Nicuolo, F., D'Alessio, M.C., Caruso, A., Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum. Reprod. Update 13 (2007), 189–196.
133. D'Ippolito, S., Meroni, P.L., Koike, T., Veglia, M., Scambia, G., Di Simone, N., Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun. Rev. 13 (2014), 901–908.
134. D'Ippolito, S., Marana, R., Di Nicuolo, F., Castellani, R., Veglia, M., Stinson, J., et al. Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS One, 7, 2012, e29660.
135. Guerin, J., Sheng, Y., Reddel, S., Iverson, G.M., Chapman, M.G., Krilis, S.A., Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J. Biol. Chem. 277 (2002), 2644–2649.
136. Girardi, G., Redecha, P., Salmon, J.E., Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10 (2004), 1222–12226.
137. de Carvalho, J.F., de Oliveira, R.M., Rodrigues, C.E.M., Glezer, A., Bonfá E., Pereira, R.M.R., Heparin increases HLA-G levels in primary antiphospholipid syndrome. Clin. Dev. Immunol. 2012 (2012), 232390–232395.
138. Cochery-Nouvellon, E., Mercier, E., Bouvier, S., Balducchi, J.-P., Quéré I., Perez-Martin, A., et al. Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. Haematologica 102 (2017), 835–842.
139. Chighizola, C.B., Shoenfeld, Y., Meroni, P.L., Therapy for antiphospholipid miscarriages: throwing the baby out with the bathwater?. Am. J. Reprod. Immunol., 27, 2017, e12792.
140. Andreoli, L., Bertsias, G.K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 76 (2017), 476–485.
141. Bates, S.M., Greer, J.A., Pabinger, I., Sofaer, S., Hirsh, J., Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008), 844S–886S.
142. Keeling, D., Mackie, I., Moore, G.W., Greer, I.A., Greaves, M., British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 157 (2012), 47–58.
143. Ramires de Jesús, G., Levy, R.A., Porter, T.F., Branch, D.W., Limited evidence for diagnosing and treating “non-criteria obstetric antiphospholipid syndrome”. Thromb. Haemostasis 114 (2015), 651–652.
144. Mak, A., Cheung, M.W.-L., Cheak, A.A.-C., Ho, R.C.-O., Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 49 (2010), 281–288.
145. Ziakas, P.D., Pavlou, M., Voulgarelis, M., Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet. Gynecol. 115 (2010), 1256–1262.
146. Empson, M., Lassere, M., Craig, J., Scott, J., Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst. Rev., 182, 2005, CD002859.
147. de Jong, P.G., Kaandorp, S., Di Nisio, M., Goddijn, M., Middeldorp, S., Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst. Rev., 7, 2014, CD004734.
148. Roberge, R., Giguère, Y., Villa, P., Nicolaides, K., Vainio, M., Forest, J.-C., et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am. J. Perinatol. 29 (2012), 551–556.
149. Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet. Gynecol. 116 (2010), 402–414.
150. Rodger, M.A., Carrier, M., Le Gal, G., Martinelli, I., Perna, A., Rey, E., et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 123 (2014), 822–828.
151. Le Thi Thuong, D., Tieulié N., Costedoat, N., Andreu, M.-R., Wechsler, B., Vauthier-Brouzes, D., et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann. Rheum. Dis. 64 (2005), 273–278.
152. Tufano, A., Coppola, A., Maruotti, G.M., Martinelli, P., Cerbone, A.M., Di Minno, G., HELLP syndrome and its relation with the antiphospholipid syndrome. Blood. Transfus. 12((2014), 114–118.
153. Spegiorin, L.C.J.F., Galão, E.A., De Godoy, J.M.P., Bagarelli, L.B., Oliani, A.H., Antiphospholipid antibodies and growth retardation in intrauterine development. Prague Med. Rep. 108 (2007), 185–190.
154. Lawley, C.M., Lain, S.J., Algert, C.S., Ford, J.B., Figtree, G.A., Roberts, C.L., Prosthetic heart valves in pregnancy: a systematic review and meta-analysis protocol. Syst. Rev., 3, 2014, 8.
155. Pauzner, R., Dulitzki, M., Langevitz, P., Livneh, A., Kenett, R., Many, A., Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb. Haemostasis 86 (2001), 1379–1384.
156. Schreiber, K., Radin, M., Sciascia, S., Current insights in obstetric antiphospholipid syndrome. Curr. Opin. Obstet. Gynecol. 29 (2017), 397–403.
157. Alijotas-Reig, J., Ferrer-Oliveras, R., Esteve-Valverde, E., Ruffatti, A., Tincani, A., Lefkou, E., et al. Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. Am. J. Reprod. Immunol. 76 (2016), 164–171.
158. Stephenson, M.D., Ballem, P.J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan, E., et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J. Obstet. Gynaecol. Can. 26 (2004), 729–734.
159. Noble, L.S., Kutteh, W.H., Lashey, N., Franklin, R.D., Herrada, J., Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil. Steril. 83 (2005), 684–690.
160. Fouda, U.M., Sayed, A.M., Abdou, A.-M.A., Ramadan, D.I., Fouda, I.M., Zaki, M.M., Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int. J. Gynaecol. Obstet. 112 (2011), 211–215.
161. Ota, K., Dambaeva, S., Han, A.-R., Beaman, K., Gilman-Sachs, A., Kwak-Kim, J., Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum. Reprod. 29 (2014), 208–219.
162. Gysler, S.M., Mulla, M.J., Stuhlman, M., Sfakianaki, A.K., Paidas, M.J., Stanwood, N.L., et al. Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast. Am. J. Reprod. Immunol. 73 (2015), 242–250.
163. Ruffatti, A., Gervasi, M.T., Favaro, M., Ruffatti, A.T., Hoxha, A., Punzi, L., Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study. Clin. Exp. Rheumatol. 29 (2011), 551–554.
164. Espinoza, J., Kusanovic, J.P., Bahado-Singh, R., Gervasi, M.T., Romero, R., Lee, W., et al. Should bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension?. J. Ultrasound Med. 29 (2010), 1103–1115.
165. Horlocker, T.T., Wedel, D.J., Rowlingson, J.C., Enneking, F.K., Kopp, S.L., Benzon, H.T., et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American society of regional anesthesia and pain medicine evidence-based guidelines (third edition). Reg. Anesth. Pain Med. 35 (2010), 64–101.
166. Østensen, M., Khamashta, M., Lockshin, M., Parke, A., Brucato, A., Carp, H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther., 8, 2006, 209.
167. Ruffatti, A., Tonello, M., Cavazzana, A., Bagatella, P., Pengo, V., Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb. Res. 123 (2009), 482–487.
168. Bouvier, S., Cochery-Nouvellon, E., Lavigne-Lissalde, G., Mercier, E., Marchetti, T., Balducchi, J.-P., et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 123 (2014), 404–413.
169. Sciascia, S., Hunt, B.J., Talavera-Garcia, E., Lliso, G., Khamashta, M.A., Cuadrado, M.J., The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol., 214, 2016, 273.
170. Erkan, D., Patel, S., Nuzzo, M., Gerosa, M., Meroni, P.L., Tincani, A., Lockshin, M.D., Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. Rheumatology, 47, 2008 iii23–27.
171. Lubbe, W.F., Butler, W.S., Palmer, S.J., Liggins, G.C., Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1 (1983), 1361–1363.
172. Lockshin, M.D., Druzin, M.L., Qamar, T., Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am. J. Obstet. Gynecol. 160 (1989), 439–443.
173. Bramham, K., Thomas, M., Nelson-Piercy, C., Khamashta, M., Hunt, B.J., First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117 (2011), 6948–6951.
174. Mekinian, A., Alijotas-Reig, J., Carrat, F., Costedoat-Chalumeau, N., Ruffatti, A., Lazzaroni, M.G., et al. Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun. Rev. 16 (2017), 730–734.
175. Marchetti, T., Ruffatti, A., Wuillemin, C., de Moerloose, P., Cohen, M., Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J. Thromb. Haemostasis 12 (2014), 910–920.
176. Wu, X.-X., Guller, S., Rand, J.H., Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am. J. Obstet. Gynecol., 205, 2011 576.e7–14.
177. Albert, C.R., Schlesinger, W.J., Viall, C.A., Mulla, M.J., Brosens, J.J., Chamley, L.W., et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am. J. Reprod. Immunol. 71 (2013), 154–164.
178. Bertolaccini, M.L., Contento, G., Lennen, R., Sanna, G., Blower, P.J., Ma, M.T., et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J. Autoimmun. 75 (2016), 30–38.
179. Parke, A., Antimalarial drugs and pregnancy. Am. J. Med. 85 (1988), 30–33.
180. Mekinian, A., Lazzaroni, M.G., Kuzenko, A., Alijotas-Reig, J., Ruffatti, A., Levy, P., et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun. Rev. 14 (2015), 498–502.
181. Sciascia, S., Branch, D.W., Levy, R.A., Middeldorp, S., Pavord, S., Roccatello, D., et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb. Haemostasis 115 (2016), 285–290.
182. Schreiber, K., Breen, K., Cohen, H., Jacobsen, S., Middeldorp, S., Pavord, S., et al. Hydroxychloroquine to improve pregnancy outcome in women with antIphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin. Thromb. Hemost. 43 (2017), 562–571.
183. Carreras, L.D., Perez, G.N., Vega, H.R., Casavilla, F., Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 2 (1988), 393–394.
184. Parke, A., Maier, D., Wilson, D., Andreoli, J., Ballow, M., Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann. Intern. Med. 110 (1989), 495–496.
185. Wapner, R.J., Cowchock, F.S., Shapiro, S.S., Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions. Am. J. Obstet. Gynecol. 161 (1989), 1271–1272.
186. Kaaja, R., Julkunen, H., Ammälä P., Palosuo, T., Kurki, P., Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet. Gynecol. Scand. 72 (1993), 63–66.
187. Arnout, J., Spitz, B., Wittevrongel, C., Vanrusselt, M., Van Assche, A., Vermylen, J., High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb. Haemostasis 71 (1994), 741–747.
188. Somerset, D.A., Raine-Fenning, N., Gordon, C., Weaver, J.B., Kilby, M.D., Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus. Eur. J. Obstet. Gynecol. Reprod. Biol. 79 (1998), 227–229.
189. Branch, D.W., Peaceman, A.M., Druzin, M., Silver, R.K., El-Sayed, Y., Silver, R.M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am. J. Obstet. Gynecol. 181 (2000), 122–127.
190. Stojanovich, L., Mikovic, Z., Mandic, V., Popovich-Kuzmanovich, D., Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin. Isr. Med. Assoc. J. 9 (2007), 555–556.
191. Mar, N., Kosowicz, R., Hook, K., Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. J. Thromb. Thrombolysis 38 (2014), 196–200.
192. Chighizola, C.B., Gerosa, M., Trespidi, L., Di Giacomo, A., Rossi, F., Acaia, B., Meroni, P.L., Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expet Rev. Clin. Immunol. 10 (2014), 1505–1517.
193. Kobayashi, S., Tamura, N., Tsuda, H., Mokuno, C., Hashimoto, H., Hirose, S., Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Ann. Rheum. Dis. 51 (1992), 399–401.
194. Nakamura, Y., Yoshida, K., Itoh, S., Kanai, Y., Tsuda, H., Hashimoto, H., et al. Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am. J. Reprod. Immunol. 41 (1999), 307–311.
195. Bortolati, M., Marson, P., Chiarelli, S., Tison, T., Facchinetti, M., Gervasi, M.T., et al. Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther. Apher. Dial. 13 (2009), 157–160.
196. Ruffatti, A., Hoxha, A., Favaro, M., Tonello, M., Colpo, A., Cucchini, U., Banzato, A., Pengo, V., Additional treatments for high-risk obstetric anti-phospholipid syndrome: a comprehensive review. Clin. Rev. Allergy Immunol. 53 (2017), 28–39.
197. Frampton, G., Cameron, J.S., Thom, M., Jones, S., Raftery, M., Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet 2 (1987), 1023–1024.
198. El-Haieg, D.O., Zanati, M.F., El-Foual, F.M., Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int. J. Gynaecol. Obstet. 99 (2007), 236–241.
199. Ruffatti, A., Marson, P., Pengo, V., Favaro, M., Tonello, M., Bortolati, M., et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun. Rev. 6 (2007), 196–202.
200. Rose, H.L., Ho, W.K., Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies. J. Thromb. Thrombolysis 38 (2014), 453–456.
201. Mayer-Pickel, K., Horn, S., Lang, U., Cervar-Zivkovic, M., Response to plasmapheresis measured by angiogenic factors in a woman with antiphospholipid syndrome in pregnancy. Case. Rep. Obstet. Gynecol., 2015, 2015 123408–6.
202. Ruffatti, A., Favaro, M., Hoxha, A., Zambon, A., Marson, P., del Ross, T., et al. Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. J. Reprod. Immunol. 115 (2016), 14–19.
203. Ruffatti, A., Salvan, E., del Ross, T., Gerosa, M., Andreoli, L., Maina, A., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb. Haemostasis 112 (2014), 727–735.
204. Redecha, P., Franzke, C.W., Ruf, W., Mackman, N., Girardi, G., Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J. Clin. Invest. 118 (2008), 3453–3461.
205. Girardi, G., Pravastatin to treat and prevent preeclampsia, Preclinical and clinical studies. J. Reprod. Immunol. 124 (2017), 15–20.
206. Bateman, B.T., Hernandez-Diaz, S., Fischer, M.A., Seely, E.W., Ecker, J.L., Franklin, J.M., et al. Statins and congenital malformations: cohort study. Br. Med. J., 350, 2015, 1035.
207. Lefkou, E., Mamopoulos, A., Dagklis, T., Vosnakis, C., Rousso, D., Girardi, G., Pravastatin improves pregnancy outcomes in obstetric antipho spholipid syndrome refractory to antithrombotic therapy. J. Clin. Invest. 126 (2016), 2933–2940.
208. Bećarević M., Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. J. Thromb. Thrombolysis 44 (2017), 565–570.
209. Leaf, R.K., Connors, J.M., The role of anticoagulants in the prevention of pregnancy complications. Clin. Appl. Thromb. Hemost. 23 (2017), 116–123.
210. Martinez-Zamora, M.A., Peralta, S., Creus, M., Tassies, D., Reverter, J.C., Espinosa, G., et al. Risk of thromboembolic events after recurrent spontan.eous abortion in antiphospholipid syndrome: a case-control study. Ann. Rheum. Dis. 71 (2012), 61–66.
211. Erkan, D., Merrill, J.T., Yazici, Y., Sammaritano, L., Buyon, J.P., Lockshin, M.D., High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 44 (2001), 1466–1467.
212. Gris, J.C., Bouvier, S., Molinari, N., Galanaud, J.P., Cochery-Nouvellon, E., Mercier, E., et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 119 (2012), 2624–2632.
213. Quenby, S., Farquharson, R.G., Dawood, F., Hughes, A.M., Topping, J., Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum. Reprod. 20 (2005), 1729–1732.
214. Silver, R.M., Draper, M.L., Scott, J.R., Lyon, J.L., Reading, J., Branch, D.W., Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet. Gynecol. 83 (1994), 372–377.
215. Drozdinsky, G., Hadar, E., Shmueli, A., Gabbay-Benziv, R., Shiber, S., Obstetric antiphospholipid syndrome and long term arterial thrombosis risk. J. Thromb. Thrombolysis 44 (2017), 371–375.
216. Asherson, R.A., The catastrophic antiphospholipid syndrome. J. Rheumatol. 19 (1992), 508–512.
217. Asherson, R.A., Cervera, R., de Groot, P.G., Erkan, D., Boffa, M.C., Piette, J.C., et al. Catastrophic Antiphospholipid Syndrome Registry Project Group, Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003), 530–534.
218. Rodríguez-Pintó I., Espinosa, G., Cervera, R., Catastrophic antiphospholipid syndrome: the current management approach. Best Pract. Res. Clin. Rheumatol. 30 (2016), 239–249.
219. Yasuda, S., Atsumi, T., Matsuura, E., Kaihara, K., Yamamoto, D., Ichikawa, K., et al. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum. 52 (2005), 212–218.
220. Sène, D., Piette, J.C., Cacoub, P., Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun. Rev. 7 (2008), 272–277.
221. Cervera, R., Rodríguez-Pintó I., Colafrancesco, S., Conti, F., Valesini, G., Rosário, C., et al. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun. Rev. 13 (2014), 699–707.
222. Canpolat, N., Topal, N., Civilibal, M., Caliskan, S., Sever, L., Kasapcopur, O., et al. A case of catastrophic antiphospholipid syndrome in an adolescent girl with parvovirus B19 infection. Clin. Pediatr. 47 (2008), 593–597.
223. Durkin, M.L., Marchese, D., Robinson, M.D., Ramgopal, M., Catastrophic antiphospholipid syndrome (CAPS) induced by influenza A virus subtype H1N1. BMJ Case Rep., 2013, 2013 bcr2013200474–4.
224. Betancur, J.F., Navarro, E.P., Bravo Bonilla, J.H., Cortés, A.D., Vélez, J.D., Echeverry, A., et al. Catastrophic antiphospholipid syndrome triggered by fulminant chikungunya infection in a patient with systemic lupus erythematosus. Arthritis Rheum., 68, 2016 1044–4.
225. Miesbach, W., Asherson, R.A., Cervera, R., Shoenfeld, Y., Gomez Puerta, J., Espinosa, G., et al. The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome. Clin. Rheumatol. 26 (2007), 2109–2114.
226. Hirsh, J., Guyatt, G., Albers, G.W., Schünemann, H.J., The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004), 172S–173S.
227. Ruffatti, A., De Silvestro, G., Ghirardello, A., Calligaro, A., Del Ross, T., Thiene, G., et al. A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation. J. Intern. Med. 235 (1994), 81–83.
228. Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., Karin, M., Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995), 286–290.
229. Bontadi, A., Ruffatti, A., Marson, P., Tison, T., Tonello, M., Hoxha, A., et al. Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J. Clin. Apher. 27 (2012), 200–204.
230. Schwartz, J., Winters, J.L., Padmanabhan, A., Balogun, R.-A., Delaney, M., Linenberger, M.L., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J. Clin. Apher. 28 (2013), 145–284.
231. Uthman, I., Shamseddine, A., Taher, A., The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus. Apher. Sci. 33 (2005), 11–17.
232. Marson, P., Bagatella, P., Bortolati, M., Tison, T., De Silvestro, G., Fabris, F., et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J. Intern. Med. 264 (2008), 201–203.
233. Bucciarelli, S., Erkan, D., Espinosa, G., Cervera, R., Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin. Rev. Allergy Immunol. 36 (2009), 80–84.
234. Berman, H., Rodríguez-Pintó I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., Erkan, D., et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun. Rev. 12 (2013), 1085–1090.
235. Rubenstein, E., Arkfeld, D.G., Metyas, S., Shinada, S., Ehresmann, S., Liebman, H.A., Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol. 33 (2006), 355–357.
236. Manner, H., Jung, B., Tonassi, L., Hackenberg, U., Plum, N., Josten, K.M., et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am. J.Med. Sci. 335 (2008), 394–397.
237. van Wissen, S., Bastiaansen, B.A.J., Stroobants, A.K., van den Dool, E.J., Idu, M.M., Levi, M., et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour–a case report. Lupus 17 (2008), 586–590.
238. Asherson, R.A., Espinosa, G., Menahem, S., Yinh, J., Bucciarelli, S., Bosch, X., et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin. Arthritis Rheum. 37 (2008), 366–372.
239. Ketari Jamoussi, S., Zaghdoudi, I., Ben Dhaou, B., Kochbati, S., Mir, K., Ben Ali, Z., et al. Catastrophic antiphospholipid syndrome and rituximab: a new report. Tunis. Med. 87 (2009), 699–702.
240. Haque, W., Kadikoy, H., Pacha, O., Maliakkal, J., Hoang, V., Abdellatif, A., Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy. Rheumatol. Int. 30 (2010), 719–723.
241. Vieregge, G.B., Harrington, T.J., Andrews, D.M., Carpintero, M.F., Green, D.F., Nayer, A., Catastrophic antiphospholipid syndrome with severe acute thrombotic microangiopathy and hemorrhagic complications. Case Rep. Med. 2013 (2013), 915309–915316.
242. Routy, B., Huynh, T., Fraser, R., Séguin, C., Vascular endothelial cell function in catastrophic antiphospholipid syndrome: a case report and review of the literature. Case. Rep. Hematol., 2013, 2013 710365–4.
243. Shiber, S., Yair, M., Catastrophic antiphospholipid syndrome: a case series. Isr. Med. Assoc. J. 15 (2013), 481–484.
244. Rosenbaum, A.N., Anavekar, N.S., Ernste, F.C., Mankad, S.V., Le, R.-J., Manocha, K.K., et al. A case of catastrophic antiphospholipid syndrome: first report with advanced cardiac imaging using MRI. Lupus 24 (2015), 1338–1341.
245. Martis, N., Blanchouin, E., Lazdunski, R., Lechtman, S., Robert, A., Hyvernat, H., et al. A therapeutic challenge: catastrophic anti-phospholipid syndrome with diffuse alveolar haemorrhage. Immunol. Res. 62 (2015), 222–224.
246. Sukara, G., Baresi, M., Sentic, M., Brcic, L., Anic, B., Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta. Reumatol. Port 40 (2015), 169–175.
247. Horikoshi, M., Inokuma, S., Matsubara, E., Honda, Y., Okada, R., Kobuna, M., et al. Atypical Subacute recurrence of catastrophic antiphospholipid syndrome in a Japanese female patient. Intern. Med. 54 (2015), 2923–2927.
248. Doğru, A., Ugan, Y., Şahin, M., Karahan, N., ŞE. Tunç Catastrophic antiphospholipid syndrome treated with rituximab: a case report. Eur. J. Rheumatol. 4 (2017), 145–147.
249. Lonze, B.E., Singer, A.L., Montgomery, R.A., Eculizumab and renal transplantation in a patient with CAPS. N. Engl. J. Med. 362 (2010), 1744–1775.
250. Shapira, I., Andrade, D., Allen, S.L., Salmon, J.E., Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum., 64, 2012 2719–2273.
251. Kronbichler, A., Frank, R., Kirschfink, M., Szilágyi, Á., Csuka, D., Prohászka, Z., et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine, 93, 2014, e143.
252. Strakhan, M., Hurtado-Sbordoni, M., Galeas, N., Bakirhan, K., Alexis, K., Elrafei, T., 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case. Rep. Hematol. 2014 (2014), 704371–704377.
253. Zikos, T.A., Sokolove, J., Ahuja, N., Berube, C., Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J. Clin. Rheumatol. 21 (2015), 311–313.
254. Wig, S., Chan, M., Thachil, J., Bruce, I., Barnes, T., A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology 55 (2016), 382–384.
255. Barbhaiya, M., Erkan, D., Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. Curr. Rheumatol. Rep. 13 (2011), 59–69.
256. Ceccarelli, F., Chighizola, C., Finazzi, G., Meroni, P.L., Valesini, G., Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “Pros” and “Cons”. Autoimmun. Rev. 11 (2012), 568–571.
257. Arnaud, L., Mathian, A., Devilliers, H., Ruffatti, A., Tektonidou, M., Forastiero, R., et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 14 (2015), 192–200.
258. Cuadrado, M.J., Bertolaccini, M.L., Seed, P.T., Tektonidou, M.G., Aguirre, A., Mico, L., et al. Low-dose aspirin vs low-dose aspirin plus low- intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology 53 (2014), 275–284.
259. Tincani, A., Andreoli, L., Shoenfeld, Y., Anti-phospholipid antibodies. Rheumatology 53 (2014), 201–202.
260. Giron-Gonzalez, J.A., Garcia del Rio, E., Rodriguez, C., Rodriguez-Martorell, J., Serrano, A., Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J. Rheumatol. 31 (2004), 1560–1567.
261. Bertsias, G., Ioannidis, J.P.A., Boletis, J., Bombardieri, S., Cervera, R., Dostál, C., et al. EULAR recommendations for the management of systemic lupus erythematosus, report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann. Rheum. Dis. 67 (2008), 195–205.
262. Bertsias, G.K., Salmon, J.E., Boumpas, D.T., Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann. Rheum. Dis. 69 (2010), 1603–1611.
263. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., Khamashta, M.A., Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69 (2010), 20–28.
264. Schreiber, K., Breen, K., Parmar, K., Rand, J.H., Wu, X.-X., Hunt, B.J., The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology 57 (2018), 120–124.
265. Erkan, D., Unlu, O., Sciascia, S., Belmont, H.M., Branch, D.W., Cuadrado, M.J., et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus, 31, 2017 961203317724219.
266. Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M., Kastelein, J.J., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009), 1175–1182.
267. López-Pedrera, C., Ruiz-Limón, P., Aguirre, M.Á., Barbarroja, N., Pérez-Sánchez, C., Buendía, P., et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann. Rheum. Dis. 70 (2011), 675–682.
268. Erkan, D., Willis, R., Murthy, V.L., Basra, G., Vega, J., Ruiz-Limon, P., et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann. Rheum. Dis. 73 (2014), 1176–1180.
269. Riancho-Zarrabeitia, L., Cubería, M., Muñoz, P., López-Hoyos, M., García-Canale, S., García-Unzueta, M., et al. Vitamin D and antiphospholipid syndrome: a retrospective cohort study and meta-analysis. Semin. Arthritis Rheum., 2017, 10.1016/j.semarthrit.2017.10.007.
270. Agmon-Levin, N., Blank, M., Zandman-Goddard, G., Orbach, H., Meroni, P.L., Tincani, A., et al. Vitamin D: an instrumental factor in the antiphospholipid syndrome by inhibition of tissue factor expression. Ann. Rheum. Dis. 70 (2011), 145–150.
271. Piantoni, S., Andreoli, L., Allegri, F., Meroni, P.L., Tincani, A., Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 64 (2012), 307–313.
272. López-Pedrera, C., Barbarroja, N., Jimenez-Gomez, Y., Collantes-Estevez, E., Aguirre, M.A., Cuadrado, M.J., Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatology 55 (2016), 2096–2108.
273. Perez-Sanchez, C., Ruiz-Limon, P., Aguirre, M.A., Bertolaccini, M.L., Khamashta, M.A., Rodriguez-Ariza, A., et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 119 (2012), 5859–5870.
274. Pérez-Sánchez, C., Aguirre, M.A., Ruiz-Limón, P., Ábalos-Aguilera, M.C., Jimenez-Gomez, Y., Arias-de la Rosa, I., et al. Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol. 37 (2017), 1923–1932.
275. Del Ross, T., Ruffatti, A., Visentin, M.S., Tonello, M., Calligaro, A., Favaro, M., et al. Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J. Rheumatol. 40 (2013), 425–429.
276. Soh, M.C., Pasupathy, D., Gray, G., Nelson-Piercy, C., Persistent antiphospholipid antibodies do not contribute to adverse pregnancy outcomes. Rheumatology 52 (2013), 1642–1647.
277. Fredi, M., Aggogeri, E., Bettiga, E., Andreoli, L., Lazzaroni, M.G., Le Guern, V., et al. A multicenter prospective evaluation of the risk profile in pregnant patients with persistent positivity for antiphospholipid antibodies (APL). Ann. Rheum. Dis., 74, 2015, 575.
278. Lazzaroni, M.G., Andreoli, L., Chighizola, C.B., Ross, T.Del, Gerosa, M., Kuzenko, A., et al. Risk factors for adverse pregnancy outcome in antiphospholipid antibodies carriers: results from a multicenter Italian cohort over 20 years of experience. Ann. Rheum. Dis., 76, 2017, 70.
279. Cowchock, S., Reece, E.A., Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am. J. Obstet. Gynecol. 176 (1997), 1099–1100.
280. Chauleur, C., Galanaud, J.P., Alonso, S., Cochery-Nouvellon, E., Balducchi, J.P., Marès, P., et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J. Thromb. Haemostasis 8 (2010), 699–706.
281. Alijotas-Reig, J., Ferrer-Oliveras, R., EUROAPS Study Group, The European registry on obstetric antiphospholipid syndrome (EUROAPS): a preliminary first year report. Lupus 21 (2012), 766–768.
282. Meroni, P.L., Prevention & treatment of obstetrical complications in APS: is hydroxychloroquine the Holy Grail we are looking for?. J. Autoimmun. 75 (2016), 1–5.
283. Abd Rahman, R., DeKoninck, P., Murthi, P., Wallace, E.M., Treatment of preeclampsia with hydroxychloroquine: a review. J. Matern. Fetal Neonatal Med. 31 (2018), 525–529.
284. Albert, C.R., Schlesinger, W.J., Viall, C.A., et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am. J. Reprod. Immunol. 71 (2014), 154–164.
285. Boffa, M.C., Boinot, C., de Carolis, S., Rovere-Querini, P., Aurousseau, M.H., Allegri, F., et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb. Haemostasis 102 (2009), 25–28.
286. Ruffatti, A., Olivieri, S., Tonello, M., Bortolati, M., Bison, E., Salvan, E., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J. Thromb. Haemostasis 6 (2008), 1693–1696.
287. Gardiner, C., Hills, J., Machin, S.J., Cohen, H., Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 22 (2013), 18–25.
288. Chighizola, C.B., Raimondo, M.G., Comerio, C., Pregnolato, F., Sobrino, C., Trespidi, L., et al. The risk of obstetric complications and the effects of treatment in women with low titer and medium-high titer anti-phospholipid antibodies. Arthritis Rheum., 68, 2016.
289. Proietta, M., Ferrero, S., Ferri, L., Cifani, N., Bruno, G., Del Porto, F., Recurrent miscarriages in women not fulfilling classification criteria for antiphospholipid antibody syndrome. Int. J. Immunopathol. Pharmacol. 27 (2014), 429–432.
290. Mekinian, A., Loire-Berson, P., Nicaise-Roland, P., Lachassinne, E., Stirnemann, J., Boffa, M.C., Chollet-Martin, S., Carbillon, L., Fain, O., Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J. Reprod. Immunol. 94 (2012), 222–226.
291. Simchen, M.J., Dulitzki, M., Rofe, G., Shani, H., Langevitz, P., Schiff, E., Pauzner, R., High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta. Obstet. Gynecol. Scand. 90 (2011), 1428–1433.
292. de Jesus, G.R., Agmon-Levin, N., Andrade, C.A., Andreoli, L., Chighizola, C.B., Porter, T.F., et al. 14th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun. Rev. 13 (2014), 795–813.
293. Rosove, M.H., Brewer, P.M., Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117 (1992), 303–308.
294. Derksen, R.H., de Groot, P.G., Kater, L., Nieuwenhuis, H.K., Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann. Rheum. Dis. 52 (1993), 689–692.
295. Khamashta, M.A., Cuadrado, M.J., Mujic, F., Taub, N., Hunt, B.J., Hughes, G.R., The management of thrombosis in the antiphospholipid antibody syndrome. N. Engl. J. Med. 332 (1995), 993–997.
296. Prandoni, P., Simioni, P., Girolami, A., Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb. Haemostasis, 75, 1996, 859.
297. Rance, A., Emmerich, J., Fiessinger, J.N., Anticardiolipin antibodies and recurrent thromboembolism. Thromb. Haemostasis 77 (1997), 221–222.
298. Krnic-Barrie, S., O'Connor, C.R., Looney, S.W., Pierangeli, S.S., Harris, E.N., A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch. Intern. Med. 157 (1997), 2101–2108.
299. Ruiz-Irastorza, G., Khamashta, M.A., Hunt, B.J., Escudero, A., Cuadrado, M.J., Hughes, G.R., Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch. Intern. Med. 162 (2002), 1164–1169.
300. Wittkowsky, A.K., Downing, J., Blackburn, J., Nutescu, E., Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb. Haemostasis 96 (2006), 137–141.
301. Okuma, H., Kitagawa, Y., Yasuda, T., Tokuoka, K., Takagi, S., Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int. J. Med. Sci. 7 (2010), 15–18.
302. Kutteh, W.H., Ermel, L.D., A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am. J. Reprod. Immunol. 35 (1996), 402–407.
303. Rai, R., Cohen, H., Dave, M., Regan, L., Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br. Med. J. 314 (1997), 253–257.
304. Laskin, C.A., Spitzer, K.A., Clark, C.A., Crowther, M.R., Ginsberg, J.S., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J. Rheumatol. 36 (2009), 279–287.
305. Many, A., Pauzner, R., Carp, H., Langevitz, P., Martinowitz, U., Treatment of patients with antiphospholipid antibodies during pregnancy. Am. J. Reprod. Immunol. 28 (1992), 216–218.
306. Passaleva, A., Massai, G., D'Elios, M.M., Livi, C., Abbate, R., Prevention of miscarriage in antiphospholipid syndrome. Autoimmunity 14 (1992), 121–125.
307. Jeremić K., Pervulov, M., Gojnić M., Dukanac, J., Ljubić A., Stojnić J., Comparison of two therapeutic protocols in patients with antiphospholipid antibodies and recurrent miscarriages. Vojnosanit. Pregl. 62 (2005), 435–439.
308. Xiao, J., Xiong, J., Zhu, F., He, L., Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp. Ther. Med. 5 (2013), 287–291.
309. Erkan, D., Yazici, Y., Peterson, M.G., Sammaritano, L., Lockshin, M.D., A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 41 (2002), 924–929.
310. Mok, M.Y., Chan, E.Y.T., Fong, D.Y.T., Leung, K.F.S., Wong, W.S., Lau, C.S., Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 32 (2005), 622–628.
311. Hereng, T., Lambert, M., Hachulla, E., Samor, M., Dubucquoi, S., Caron, C., et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 17 (2008), 11–15.
312. Tarr, T., Lakos, G., Bhattoa, H.P., Shoenfeld, Y., Szegedi, G., Kiss, E., Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 16 (2007), 39–45.
313. Ruffatti, A., del Ross, T., Ciprian, M., Bertero, M.T., Sciascia, S., Salvatore, S., et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann. Rheum. Dis. 70 (2011), 1083–1086.
314. Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118 (2011), 4714–4718.
315. Mustonen, P., Lehtonen, K.V., Javela, K., Puurunen, M., Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 23 (2014), 1468–1476.
316. Pengo, V., Testa, S., Martinelli, I., Ghirarduzzi, A., Legnani, C., Gresele, P., Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb. Res. 135 (2015), 46–49.
317. Chighizola CB, Pregnolato F, Andreoli L, et al. Beyond thrombosis: anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J. Autoimmun. This issue.